Pharmacokinetic and Pharmacodynamic Interaction of Lorazepam and Valproic Acid in Relation to UGT2B7 Genetic Polymorphism in Healthy Subjects

• Published in: Clinical pharmacology and therapeutics 2008-04, Vol.83 (4), p.595-600
• Main Authors: Chung, J‐Y, Cho, J‐Y, Yu, K‐S, Kim, J‐R, Lim, KS, Sohn, D‐R, Shin, S‐G, Jang, I‐J
• Format: Article
• Language: English
• Subjects: Adult; Anticonvulsants - administration & dosage; Anticonvulsants - blood; Anticonvulsants - pharmacokinetics; Anticonvulsants - pharmacology; Area Under Curve; Female; Glucuronosyltransferase - genetics; Humans; Lorazepam - administration & dosage; Lorazepam - blood; Lorazepam - pharmacokinetics; Lorazepam - pharmacology; Male; Polymorphism, Genetic; Psychometrics; Psychomotor Performance - drug effects; Valproic Acid - administration & dosage; Valproic Acid - blood; Valproic Acid - pharmacokinetics; Valproic Acid - pharmacology
• ISSN: 0009-9236; 1532-6535
• DOI: 10.1038/sj.clpt.6100324

Pharmacokinetic and pharmacodynamic profiles of lorazepam and valproate were analyzed according to uridine 5′‐diphosphate‐glucuronosyltransferase (UGT)2B7 genotype in 14 healthy subjects with UGT2B15*2/*2 genotype. Systemic clearance of lorazepam (2 mg intravenously) and area under the concentration–time curve (AUC) of valproate (600 mg once daily for 4 days) were analyzed as pharmacokinetic parameters, and area under the effect–time curve (AUEC) of psychomotor coordination tests (Vienna) was used for pharmacodynamic parameter. No significant differences were found in systemic clearances of lorazepam by UGT2B7 genotype. AUCs of valproate showed an increasing tendency as the number of UGT2B7*2 alleles increased, but the difference was insignificant. Psychometric results were significant among the UGT2B7 genotype group (AUEC_tracking 261.5±298.9 in *1/*1, and 3,396.8±947 in *2/*2, P=0.047) when the two drugs were coadministered. Our study suggests that the UGT2B7 genotype probably affects lorazepam–valproate pharmacodynamic interaction, especially in subjects who have homovariant genotypes of UGT2B7 and UGT2B15, although the effects on the pharmacokinetics are less significant. Clinical Pharmacology & Therapeutics (2008); 83, 4 595–600. doi:10.1038/sj.clpt.6100324